TVM Capital Life Science invests in disruptive life science innovations with a two-pronged strategy: financing early-stage therapeutics through a strategic partnership with Eli Lilly and investing in differentiated commercial-stage medtech, diagnostics, digital health, and late-stage therapeutics. The firm leverages AI-driven approaches in drug development and partners closely with portfolio companies to accelerate market adoption of transformative medical products.
Preferred startup development maturity for initial funding deployment.
Early-stage therapeutics, commercial-stage medtech, diagnostics, digital health, and late-stage therapeutics with a focus on AI-driven drug development
Core thematic spaces, technologies, and target market segments of interest.
Standard financial allocation per investment round.
Direct Verification Contact Email Pattern
Thesis Dossier Analysis Scorecard
Our agent analyzer scanned portfolio holdings and verified absolute match parameters...
Investment Team (39)
Amy Kao
Amy Kao, PhD
Barbara Hauser
Bien Kiat Tan
Catello Somma
Dominique Larose
Dr. Alain Thibault
Dr. Axel Polack
Dr. Helmut M. Schuehsler

Dr. Hubert Birner

Dr. Luc Marengère
Dr. Schuehsler

